XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.20 and traded as high as $2.64. XORTX Therapeutics shares last traded at $2.44, with a volume of 32,581 shares trading hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XORTX Therapeutics in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, XORTX Therapeutics presently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on XRTX
XORTX Therapeutics Stock Performance
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last released its quarterly earnings results on Saturday, August 15th. The technology company reported ($1.05) earnings per share for the quarter.
Institutional Investors Weigh In On XORTX Therapeutics
An institutional investor recently bought a new stake in XORTX Therapeutics stock. DRW Securities LLC purchased a new stake in XORTX Therapeutics Inc. (NASDAQ:XRTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 193,599 shares of the technology company’s stock, valued at approximately $109,000. DRW Securities LLC owned 2.78% of XORTX Therapeutics as of its most recent filing with the SEC. 0.23% of the stock is currently owned by hedge funds and other institutional investors.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.
Further Reading
- Five stocks we like better than XORTX Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
